Evaluating FcRN, FcyR, & IgG Biology for Targeting & Antibody Engineering to Advance Molecular Development, Clinical Utility, & Novel Therapeutic Applications
Welcome to the Industry-led Conference Dedicated to Driving Innovation in the Development of Fc-Mediated Therapeutics
The landscape of Fc-mediated therapies is undergoing a radical transformation, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification.
This year, we're evaluating the cutting-edge of Fc biology and engineering, diving deep into the game-changing potential of novel Fc modifications, bispecific formats, and targeted effector functions to revolutionize the treatment of cancer, autoimmune diseases, and beyond. Hear from the titans of the pharmaceutical industry, including AbbVie, Novartis, and UCB as well as innovative biotechs including Seismic Therapeutics, Paradigm Immunotherapies, and many more – as they share their groundbreaking research and strategies for developing more effective, safer, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year’s wave in FDA approvals from BeiGene’s Tevimbra to Genetech’s approval of Piasky, and the pressure is on to continue this success and develop best-in-class treatments.
Don't miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function, forge crucial collaborations, and be part of the solution. The future of antibody therapeutics is being written now – be a part of it!
World-Class Speaker Faculty Includes:






Previously Attending Companies Include:

“Top presentations, plenty of networking opportunities, excellent crowd.”
Senior Scientist, Genmab


“Excellent speakers and the 2 days were packed with a good mix of discovery and clinical science.”
Chief Scientific Officer, Cyrus Biotechnology Inc.



2025 Partners

